Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug

Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug

CDE Grants Priority Review Status to Kechow’s HL-085 for Melanoma Treatment

Fineline Cube Jan 30, 2023

The Center for Drug Evaluation (CDE) website indicates that Kechow Pharma’s HL-085 is set to...

Company Drug

NMPA Approves Two China-Developed COVID-19 Small-Molecule Therapies

Fineline Cube Jan 29, 2023

The National Medical Products Administration (NMPA) has issued conditional marketing approvals to two novel, China-discovered...

Policy / Regulatory

China’s NHC Issues Guidelines to Improve Pediatric Medication Management

Fineline Cube Jan 29, 2023

The National Health Commission (NHC) has released a notification aimed at refining management measures for...

Policy / Regulatory

China’s Multi-Bureau Plan Aims to Eradicate Cervical Cancer by 2030

Fineline Cube Jan 29, 2023

The National Health Commission (NHC), Ministry of Education, Ministry of Civil Affairs, and six other...

Company Drug

JS InnoPharm’s US Subsidiary Initiates Phase I Trial for AURKA Inhibitor VIC-1911

Fineline Cube Jan 29, 2023

Shanghai-based JS InnoPharm Ltd has announced the initiation of a Phase I clinical study by...

Company Deals

Akeso Receives First $300M Installment from Summit for Bispecific Antibody Ivonescimab

Fineline Cube Jan 29, 2023

Akeso Inc. (HKG: 9926) has announced receiving the first installment of USD 300 million as...

Policy / Regulatory

NMPA Proposes Emergency Use Management Measures for Medical Devices

Fineline Cube Jan 29, 2023

The National Medical Products Administration (NMPA) has released the “Medical Device Emergency Use Management Measures”...

Company Drug

InnoCare’s Gunagratinib Shows Promising Data in Cholangiocarcinoma at ASCO-GI 2023

Fineline Cube Jan 29, 2023

Beijing InnoCare Pharma Tech Co. (HKG: 9969), a China-based biotech specializing in cancer and autoimmune...

Company Drug

Exegenesis Bio Gains FDA Approval for Gene Therapy EXG102-031 in Wet AMD

Fineline Cube Jan 29, 2023

Hangzhou-based clinical stage gene therapy firm Exegenesis Bio has announced receiving approval from the US...

Company Drug

Simcere’s Cosela Receives First Prescription in China for CDK4/6 Inhibition

Fineline Cube Jan 29, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the issuance of the first prescription for...

Policy / Regulatory

China Updates Export Controls on Technologies, Adds Gene Editing to List

Fineline Cube Jan 29, 2023

The Ministry of Finance (MOF) has released an updated notification regarding technologies banned and restricted...

Company Drug

Novartis’ Kisqali Receives NMPA Approval for Premenopausal Breast Cancer

Fineline Cube Jan 28, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced receiving marketing approval from the National Medical...

Company Drug

Fosun Pharma’s Comirnaty Bivalent Vaccine Approved in Macau for Booster Shots

Fineline Cube Jan 28, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its Comirnaty...

Company Drug

HuidaGene Receives FDA IND Approval for Ophthalmology Gene Therapy HG004

Fineline Cube Jan 28, 2023

China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced receiving Investigational New Drug (IND) approval from...

Company Deals

Yinghe Brain Science Raises RMB 100 Million in Angel Financing Round

Fineline Cube Jan 28, 2023

Shenzhen Yinghe Brain Science Co., Ltd, a China-based neurotechnology firm, has reportedly raised over RMB...

Company Deals

HutchMed Signs Licensing Deal with Takeda for Global Fruquintinib Development

Fineline Cube Jan 28, 2023

Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced a licensing deal with Japanese...

Company Deals

Tianjin-Based Protein T Raises RMB 100 Million in Series A Financing

Fineline Cube Jan 28, 2023

Tianjin-based biotech Protein T, focused on multi-omics research, has reportedly raised close to RMB 100...

Company Drug

Ascletis Receives IND Approval for ASC10 in Monkeypox Treatment

Fineline Cube Jan 28, 2023

China-based Ascletis Pharma Inc. (HKG: 1672) has announced receiving Investigational New Drug (IND) approval from...

Company Drug

Legend Biotech’s Carvykti Meets Primary Endpoint in CARTITUDE-4 Phase III Study

Fineline Cube Jan 28, 2023

Legend Biotech (NASDAQ: LEGN) has released positive data from the CARTITUDE-4 Phase III study, evaluating...

Company Drug

CSPC’s Octreotide Long-Acting Injection Approved for Acromegaly Clinical Study

Fineline Cube Jan 20, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical...

Posts pagination

1 … 623 624 625 … 719

Recent updates

  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
  • Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips
  • GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility
  • Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications
  • Bayer’s Sevabertinib Granted FDA Accelerated Approval – First‑Line Oral TKI for HER2‑Mutant Non‑Small Cell Lung Cancer
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.